2023 World Conference on Lung Cancer (Posters)-EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC)

EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC) - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses an exploratory clinical study on the use of anlotinib combined with concurrent chemoradiotherapy in the treatment of small cell lung cancer (SCLC). SCLC accounts for 15% of all lung cancer cases, with limited-stage disease (LS-SCLC) and extensive-stage disease (ES-SCLC) being the two main types. The prognosis for SCLC patients is poor, with a 5-year survival rate of only 5%. Currently, there is a lack of safety and efficacy data for anti-angiogenesis combined with concurrent chemoradiotherapy and maintenance therapy for SCLC. Anlotinib is a multi-target tyrosine kinase inhibitor that inhibits tumor angiogenesis and proliferative signaling. It has been approved as a third-line therapy for advanced non-small cell lung cancer. Previous studies have shown that antiangiogenic therapy combined with chemotherapy has a synergistic anti-tumor effect. This study aimed to evaluate the safety and efficacy of anlotinib combined with concurrent chemoradiotherapy in SCLC patients. The main inclusion criteria were patients with inoperable LS-SCLC or ES-SCLC who had not received prior treatment. Patients were treated with anlotinib, etoposide, and cisplatin or carboplatin. After one cycle of treatment, patients were evaluated and appropriate patients received radiotherapy and continued with anlotinib maintenance treatment. The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. As of March 31, 2023, 18 patients were enrolled in the study, and 14 patients were included in the evaluation. The study showed good efficacy with an ORR of 64.3% and a DCR of 92.9%. The median PFS was 14.5 months. Common side effects included hypertension and bone marrow suppression. The study concluded that anlotinib combined with concurrent chemoradiotherapy in the treatment of SCLC has good efficacy and controllable safety, and further research is ongoing.

Asset Subtitle

Fujun Yang

Meta Tag

Speaker Fujun Yang

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

exploratory clinical study

anlotinib

concurrent chemoradiotherapy

small cell lung cancer

SCLC

efficacy

safety

progression-free survival

objective response rate

common side effects